Search

Compugen Ltd

Uždarymo kaina

2.35 0.43

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.27

Max

2.37

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-65M

-7.7M

Pardavimai

-65M

2.2M

P/E

Sektoriaus vid.

5.95

64.641

Pelnas, tenkantis vienai akcijai

-0.08

Pelno marža

-352.436

Darbuotojai

75

EBITDA

-64M

-7.7M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+112.77% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-45M

225M

Ankstesnė atidarymo kaina

1.92

Ankstesnė uždarymo kaina

2.35

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-31 23:56; UTC

In after-market trading, Invesco Ltd shares are lower, moving from a high of 0.51% to a low of -0.81%. No specific news was identified.

2026-07-31 23:56; UTC

Social Media

Equifax Inc. shares are higher in after-market trading, buoyed by CEO Mark Begor's outlook on strong cash flow and $1.6 billion returned to shareholders.

2026-07-31 23:56; UTC

Dutch Bros Inc. shares are lower in after-market trading, fluctuating within a routine range since Friday's close. The price remains stable in its one-month trading range.

2026-07-31 23:56; UTC

MannKind Corp shares traded lower in after-market hours, retreating from earlier gains. The stock remains near the lower end of its one-month range.

2026-07-31 23:56; UTC

News

Citigroup maintained its Buy rating on Welltower and raised its price target to $275. Shares are modestly higher in after-market trading.

2026-07-31 23:56; UTC

iShares 1-3 Year Treasury Bond ETF trading roughly flat in after-market hours. Global equity indices are mixed, with U.S. markets lower and others higher.

2026-07-31 23:56; UTC

Indie Semiconductor Inc. shares are near unchanged in after-market trading, following a notable decline over the past month and remaining below the 20-day moving average.

2026-07-31 23:56; UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

2026-07-31 23:56; UTC

ETF Constituents

Vanguard Real Estate ETF trading was roughly flat after hours, with CSGP, VNO, and IIPR contributing negatively while ADC provided a modest positive impact.

2026-07-31 23:56; UTC

AeroVironment Inc shares are lower in after-market hours, with no specific news identified. The stock is near the lower end of its one-month range.

2026-07-31 23:56; UTC

Transocean Ltd shares are higher in after-market trading, continuing a trend of gains over the past three sessions. No specific news was identified for the move.

2026-07-31 23:56; UTC

Comcast shares are higher in after-market trading, showing volatility with no specific news to explain the movement. Broader market trends include gains in the Nikkei 225.

2026-07-31 23:56; UTC

Correlated Moves

Texas Instruments Inc. shows little change in after-market trading, reflecting broader weakness in the technology sector amid mixed Asian market performance.

2026-07-31 23:56; UTC

Barnes Group Inc. shares declined in after-market trading, showing minor fluctuations without specific news. Asian market results provided broader context for the movement.

2026-07-31 23:56; UTC

Diamondback Energy Inc shares are higher in after-market trading, continuing recent upward momentum and reflecting strong investor interest amid no specific news.

2026-07-31 23:56; UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

2026-07-31 23:56; UTC

Marathon Digital Holdings shares are higher in after-market trading, reflecting routine activity with no specific news identified. The stock remains below its 20-day moving average.

2026-07-31 23:56; UTC

MSCI Inc. shares advanced in after-market trading, supported by a rise in the Nikkei 225 Index and renewed interest in AI stocks.

2026-07-31 23:56; UTC

Block Inc shares are higher in after-market trading, buoyed by strong earnings from U.S. tech companies that eased concerns about AI infrastructure spending.

2026-07-31 23:56; UTC

Correlated Moves

Procter & Gamble Co shares declined in after-market trading, reflecting broader sector trends as Kimberly-Clark Corp also reported a drop.

2026-07-31 23:56; UTC

Adobe Inc shares are lower in after-market hours, with no specific news identified. The stock has declined since Friday's close, amid mixed broader market trends.

2026-07-31 23:52; UTC

Mexican Inflation Rate Set for Release Amid Mixed Market Sentiment and Global Price Pressures

2026-07-31 23:52; UTC

Mexico's Inflation Rate Release on August 7, 2026, Amidst Global Economic Pressures and Mixed Market Sentiment.

2026-07-31 23:52; UTC

South Korea's July Exports Expected to Grow 0.59% YoY Amid Cautious Optimism Following Record Highs

2026-07-31 23:52; UTC

Rising MBA 30-Year Mortgage Rates Reach Highest Levels Since Last Year, Signaling Caution Among Homebuyers Amid Economic Pressures.

2026-07-31 23:51; UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

2026-07-31 23:51; UTC

Social Media
Correlated Moves
News

Meta Platforms Inc shares are lower in after-market hours, pressured by broader market weakness and concerns over rising AI spending following a disappointing earnings report.

2026-07-31 23:51; UTC

Interactive Brokers Group Inc is lower in after-market trading, reflecting the broader market's significant decline and a position below its 20-day moving average.

2026-07-31 23:51; UTC

Solaredge Technologies Inc shares declined in after-hours trading, reflecting broader market trends. No specific company news was identified to explain the movement.

2026-07-31 23:51; UTC

Evolent Health Inc shares are higher in after-market hours, rebounding from nine consecutive daily declines despite remaining below their 20-day moving average.

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

112.77% į viršų

12 mėnesių prognozė

Vidutinis 5 USD  112.77%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

3

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
help-icon Live chat